Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» PCSK9 inhibitors
PCSK9 inhibitors
Merck bets big on oral PCSK9 inhibitor, putting 6-year outcome study at heart of phase 3 program
Merck bets big on oral PCSK9 inhibitor, putting 6-year outcome study at heart of phase 3 program
Fierce Biotech
Merck
PCSK9 inhibitors
clinical trials
cardiovascular disease
cholesterol
MK-0616
Flag link:
Cholesterol-focused Esperion loses appetite for oral PCSK9 collab with Serometrix
Cholesterol-focused Esperion loses appetite for oral PCSK9 collab with Serometrix
Fierce Biotech
Esperion Therapeutics
R&D
Serometrixjm
PCSK9 inhibitors
cholesterol
Flag link:
Junshi's lipid lowering drug hits phase 3 goals, teeing up challenge to Amgen, Sanofi in growth market
Junshi's lipid lowering drug hits phase 3 goals, teeing up challenge to Amgen, Sanofi in growth market
Fierce Biotech
Junshi Biosciences
Amgen
Sanofi
China
clinical trials
PCSK9 inhibitors
Flag link:
PCSK9 pipeline shows signs of saturation
PCSK9 pipeline shows signs of saturation
EP Vantage
AstraZeneca
ION449
Ionis Pharmaceuticals
Novartis
Leqvio
PCSK9 inhibitors
Flag link:
Can A New Cholesterol Drug Restore Merck’s Prominence In Heart Drugs?
Can A New Cholesterol Drug Restore Merck’s Prominence In Heart Drugs?
Forbes
Merck
cholesterol
PCSK9 inhibitors
MK-0616
Zocor
Flag link:
Merck’s Anti-Cholesterol Drug Threatens Esperion, Other PCSK9 Inhibitor Makers
Merck’s Anti-Cholesterol Drug Threatens Esperion, Other PCSK9 Inhibitor Makers
BioSpace
Merck
PCSK9 inhibitors
Amgen
Repatha
Esperion
Sanofi
Regeneron
Praluent
Flag link:
Merck looks to ditch the needles with its next-gen oral PCSK9 inhibitor for high cholesterol
Merck looks to ditch the needles with its next-gen oral PCSK9 inhibitor for high cholesterol
Endpoints
Merck
MK-0616
oral PCSK9 inhibitors
PCSK9 inhibitors
Flag link:
Amgen dealt another blow in closely watched PCSK9 patent case against Sanofi, Regeneron
Amgen dealt another blow in closely watched PCSK9 patent case against Sanofi, Regeneron
Fierce Pharma
Amgen
PCSK9 inhibitors
Sanofi
Regeneron
patents
Repatha
Flag link:
AZ buys oral PCSK9 cholesterol drug from Dogma Therapeutics
AZ buys oral PCSK9 cholesterol drug from Dogma Therapeutics
Pharmaforum
AstraZeneca
Dogma Therapeutics
cholesterol
PCSK9 inhibitors
Flag link:
ACC: New owner Novartis presents pooled inclisiran data cutting LDL cholesterol by half
ACC: New owner Novartis presents pooled inclisiran data cutting LDL cholesterol by half
Fierce Biotech
Novartis
ACC
PCSK9 inhibitors
inclisiran
Flag link:
MedCo's PCSK9 challenger steals the show at ESC with winning data
MedCo's PCSK9 challenger steals the show at ESC with winning data
Fierce Pharma
Medicines Company
ESC
PCSK9 inhibitors
inclisiran
Repatha
Praluent
European Society of Cardiology
Flag link:
Sanofi, Regeneron score win against Amgen patents on PCSK9 med Repatha
Sanofi, Regeneron score win against Amgen patents on PCSK9 med Repatha
Fierce Pharma
Sanofi
Regeneron
Amgen
PCSK9 inhibitors
patents
Praluent
Repatha
Flag link:
Lackluster Amgen, Sanofi PCSK9 drugs could be under major threat from a new rival: analyst
Lackluster Amgen, Sanofi PCSK9 drugs could be under major threat from a new rival: analyst
Fierce Pharma
Amgen
Regeneron
Sanofi
Praluent
Repatha
Medicines Company
PCSK9 inhibitors
inclisiran
Flag link:
New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)
New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)
Xconomy
PCSK9 inhibitors
Medicines Company
inclisiran
insurers
Flag link:
Will The Introduction Of A Third Potent Cholesterol Lowering Drug Expand or Shrink The Market?
Will The Introduction Of A Third Potent Cholesterol Lowering Drug Expand or Shrink The Market?
Forbes
The Medicines Company
Amgen
Sanofi
Regeneron
inclisiran
PCSK9 inhibitors
Flag link:
Regeneron, Sanofi cut PCSK9 list price, matching earlier move by rival Amgen
Regeneron, Sanofi cut PCSK9 list price, matching earlier move by rival Amgen
Biopharma Dive
Regeneron
Sanofi
Amgen
Praluent
Repatha
drug pricing
PCSK9 inhibitors
Flag link:
New drug options, risk factors added to US heart guidelines
New drug options, risk factors added to US heart guidelines
Reuters
statins
PCSK9 inhibitors
Flag link:
Citing appeals court 'anarchy,' Amgen asks SCOTUS to weigh its PCSK9 patent spat with Sanofi
Citing appeals court 'anarchy,' Amgen asks SCOTUS to weigh its PCSK9 patent spat with Sanofi
Fierce Pharma
Amgen
Sanofi
Regeneron
PCSK9 inhibitors
Supreme Court
Praluent
Repatha
Flag link:
Are These Disappointing Drugs Back on Track to Billions?
Are These Disappointing Drugs Back on Track to Billions?
Motley Fool
PCSK9 inhibitors
Sanofi
Regeneron
Amgen
Praluent
Repatha
Flag link:
PCSK9s appear to be meeting less payer resistance
PCSK9s appear to be meeting less payer resistance
Biopharma Dive
PCSK9 inhibitors
payers
Flag link:
Pages
1
2
3
4
5
6
7
8
next ›
last »